<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To understand the prevalence, investigate the correlation of clinical features, explore the early-stage diagnosis and treatment of pulmonary arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo> (<z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi>) in patients with <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disease</z:e> (CTD) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: <z:hpo ids='HP_0000001'>All</z:hpo> cases with pulmonary arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo> in 1892 CTD patients were analyzed retrospectively </plain></SENT>
<SENT sid="2" pm="."><plain>The risk factor of <z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi> was evaluated and the prognostic influence of different treatments and <z:e sem="disease" ids="C0277554" disease_type="Disease or Syndrome" abbrv="">primary diseases</z:e> analyzed </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The prevalence of <z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi> in patients with <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disease</z:e> was about 4.2%(79/1892) </plain></SENT>
<SENT sid="4" pm="."><plain>In these patients, systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> (SSc) and <z:e sem="disease" ids="C0026272" disease_type="Disease or Syndrome" abbrv="MCTD">mixed connective tissue disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCTD</z:e>) had the highest incidence of <z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi> (18.18% and 12.00%) (P &lt; 0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>It was obviously higher than <z:e sem="disease" ids="C0085655" disease_type="Disease or Syndrome" abbrv="">polymyositis</z:e>/<z:e sem="disease" ids="C0011633" disease_type="Disease or Syndrome" abbrv="">dermatomyositis</z:e> (6.2%), <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (4.4%), <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sjogren syndrome</z:e> (3.8%), <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (0.8%) and anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> syndrome (0.5%), etc </plain></SENT>
<SENT sid="6" pm="."><plain>(P &lt; 0.01) </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0034735" disease_type="Disease or Syndrome" abbrv="">Raynaud's phenomenon</z:e> was related to a higher pulmonary arterial pressure (P &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>There was a positive correlation (P &lt; 0.01) between the presence of <z:e sem="disease" ids="C0034735" disease_type="Disease or Syndrome" abbrv="">Raynaud's phenomenon</z:e> and pulmonary arterial pressure </plain></SENT>
<SENT sid="9" pm="."><plain>Abnormal lung function was a common finding </plain></SENT>
<SENT sid="10" pm="."><plain>There were associations (P &lt; 0.05) between the degree of <z:hpo ids='HP_0002092'>pulmonary hypertension</z:hpo> and IgG, anti-U1RNP antibody positive, <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> positive, <z:hpo ids='HP_0001698'>pericardial effusion</z:hpo> and interstitial <z:hpo ids='HP_0002090'>pneumonia</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: <z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi> is common in <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disease</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>SSc and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCTD</z:e> have the highest prevalence of <z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi> </plain></SENT>
<SENT sid="13" pm="."><plain>The presence of <z:e sem="disease" ids="C0034735" disease_type="Disease or Syndrome" abbrv="">Raynaud's phenomenon</z:e> anti-U1RNP antibody is positively correlated with pulmonary arterial pressure </plain></SENT>
<SENT sid="14" pm="."><plain>It can predict the development of <z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi> </plain></SENT>
<SENT sid="15" pm="."><plain>It is useful to perform ultraechocardiogrphy for an early-stage diagnosis and prognostic analysis </plain></SENT>
</text></document>